You are here:Home-Research Areas-Other Indications-Other Indication

Request The Product List ofOther Indication Other Indication

Cat. No. Product Name CAS No. Information
PC-61856

EPI 743

1213269-98-7 EPI 743 (Vatiquinone) is an orally bioavailable para-benzoquinone for treatment of inherited mitochondrial diseases, an analogue of the antioxidant ubidecarenone.

Other Indication

Phase 3 Clinical

PC-61796

Trofinetide

853400-76-7 Trofinetide (NNZ 2566 ) is a peptidomimetic tripeptide Gly-Pro-Glu that has anti-inflammatory and neuroprotective properties against hypoxic-ischemic brain injury and neurodegeneration; improves functional recovery and attenuates apoptosis and inflammation in a rat model of penetrating ballistic-type brain injury; significantly reduces injury-mediated up-regulation of IL-1beta, TNF-alpha, E-selectin and IL-6 mRNA in the injured brain in rats.

Other Indication

Phase 2 Clinical

PC-61729

Revexepride

219984-49-3 Revexepride (SSP 002358;SPD-557) potent, highly selective 5-HT4 receptor agonist for the treatment of gastroesophageal reflux disease.

Other Indication

Phase 2 Discontinued

PC-61677

ATN-224

649749-10-0 ATN-224 (Choline tetrathiomolybdate;WTX-101) is a specific, high-affinity copper binder that inhibits CuZn superoxide dismutase 1 (SOD1) with IC50 of 0.33 uM against purified bovine SOD1, leading to antiangiogenic and antitumour effects; shows no binding to calcium, iron, magnesium, zinc, or manganese ions at 1 mM; inhibits HUVEC proliferation with IC50 1.4 uM; shows a potential therapy against Wilson's disease.

Other Indication

Phase 3 Clinical

PC-61661

JNJ 39220675

959740-39-7 JNJ 39220675 is potent and selective, brain penetrant H3 antagonist with Ki of 1.4 nM, pA2 of 9.42 for hH3; dose-dependently reduces both alcohol intake and preference in alcohol-preferring rats, reduces alcohol self-administration without changing saccharin self-administration in alcohol non-dependent rats.

Other Indication

Phase 2 Discontinued

PC-61624

RO-5459072

RO 5459072 (RG-7625) is a potent, highly selective of cathepsin S with IC50 of 0.1 nM and 0.3 nM for human and murine Cathepsin S, respectively; shows no sub-micro molar inhibition against others cathepsins (Cat L, B, K, and F) with the exception of Cat V (IC50=700  nM); dose-dependently reverses aberrant systemic autoimmunity, e.g. plasma cytokines, activation of myeloid cells and hypergammaglobulinemia, especially suppresses IgG autoantibody production.

Other Indication

Phase 2 Clinical

PC-61559

PF-04634817 succinate

2140301-98-8 PF-04634817 is a potent, orally bioavailble CCR2 and CCR5 chemokine receptor antagonist, for the treatment of diabetic nephropathies and diabetic macular oedema.

Other Indication

Phase 2 Discontinued

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com